Mäkelä A L, Olkkola K T, Mattila M J
Department of Pediatrics, University Central Hospital, Turku, Finland.
Eur J Clin Pharmacol. 1991;41(1):79-81. doi: 10.1007/BF00280114.
Ten children with rheumatoid arthritis, aged 7-16 y and weighing 20-63 kg, were treated with piroxicam mean dose 0.4 mg.kg-1 once daily for 2 weeks. On Day 15, blood was sampled from 2-120 h after the last dose. The Cmax for piroxicam ranged from 3.6 to 9.8 (mean 6.6) mg.l-1 and its half-life by log linear computation was 22 to 40 (mean 32.6) h. The volumes of distribution and the total body clearance were estimated as the ratio of actual volumes of distribution and actual clearances to availability. The volumes of distribution (V/F) were 0.12 to 0.25 (mean 0.16) l.kg-1, and the total body clearances (CL/F) were 2.1 to 5.0 (mean 3.4) ml.kg-1.h-1. Thus, piroxicam clearance in these patients was higher and its half-life was shorter than those previously reported in young adults, yet V appeared similar.
10名患有类风湿性关节炎的儿童，年龄在7至16岁之间，体重20至63千克，接受了吡罗昔康治疗，平均剂量为0.4毫克/千克，每日一次，持续2周。在第15天，于最后一剂药物后的2至120小时采集血液样本。吡罗昔康的Cmax范围为3.6至9.8（平均6.6）毫克/升，通过对数线性计算其半衰期为22至40（平均32.6）小时。分布容积和全身清除率通过实际分布容积与实际清除率与可利用性的比值进行估算。分布容积（V/F）为0.12至0.25（平均0.16）升/千克，全身清除率（CL/F）为2.1至5.0（平均3.4）毫升/千克·小时。因此，这些患者中吡罗昔康的清除率较高，其半衰期较年轻成年人先前报道的更短，但V似乎相似。
